New drug combo offers hope for kids with tough leukemia

NCT ID NCT04898894

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 23 times

Summary

This early-stage study tests the safety and best dose of two drugs, selinexor and venetoclax, when given with standard chemotherapy to children and young adults whose acute myeloid leukemia (AML) has returned or not responded to treatment. About 37 participants will receive the combination to see if it can help achieve remission. The goal is to find a tolerable dose and measure how well the treatment works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, IN RELAPSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Childrens Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Cook Children's Medical Center

    Fort Worth, Texas, 76104, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Memorial Sloan-Kettering Cancer Center

    New York, New York, 10065, United States

  • Rady Children's Hospital-San Diego

    San Diego, California, 92123, United States

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

  • UT Southwestern/Simmons Cancer Center

    Dallas, Texas, 75390, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.